Enzymatica publ AB - Asset Resilience Ratio
Enzymatica publ AB (ENZY) has an Asset Resilience Ratio of 22.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Enzymatica publ AB balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Enzymatica publ AB's Asset Resilience Ratio has changed over time. See shareholders equity of Enzymatica publ AB for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Enzymatica publ AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ENZY company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr33.08 Million | 22.17% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr33.08 Million | 22.17% |
Asset Resilience Insights
- Good Liquidity Position: Enzymatica publ AB maintains a healthy 22.17% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Enzymatica publ AB Industry Peers by Asset Resilience Ratio
Compare Enzymatica publ AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Reyon Pharmaceutical Co Ltd
KO:102460 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Moberg Pharma AB (publ)
ST:MOB |
Drug Manufacturers - Specialty & Generic | 5.24% |
|
AptaBio Therapeutics Inc
KQ:293780 |
Drug Manufacturers - Specialty & Generic | 1.57% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Canopy Growth Corp
NASDAQ:CGC |
Drug Manufacturers - Specialty & Generic | 0.45% |
|
Zhejiang Nhu Co Ltd
SHE:002001 |
Drug Manufacturers - Specialty & Generic | 4.38% |
|
IOL Chemicals and Pharmaceuticals Limited
NSE:IOLCP |
Drug Manufacturers - Specialty & Generic | 13.27% |
|
Beijing Science Sun Pharmaceutical Co Ltd
SHE:300485 |
Drug Manufacturers - Specialty & Generic | 43.40% |
Annual Asset Resilience Ratio for Enzymatica publ AB (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Enzymatica publ AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 38.53% | Skr75.21 Million ≈ $8.09 Million |
Skr195.22 Million ≈ $21.01 Million |
+31.88pp |
| 2023-12-31 | 6.64% | Skr8.37 Million ≈ $900.32K |
Skr125.91 Million ≈ $13.55 Million |
-22.42pp |
| 2022-12-31 | 29.06% | Skr50.69 Million ≈ $5.45 Million |
Skr174.41 Million ≈ $18.77 Million |
+8.93pp |
| 2021-12-31 | 20.13% | Skr31.62 Million ≈ $3.40 Million |
Skr157.04 Million ≈ $16.90 Million |
+5.31pp |
| 2020-12-31 | 14.82% | Skr24.02 Million ≈ $2.58 Million |
Skr162.03 Million ≈ $17.44 Million |
-- |
About Enzymatica publ AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.